SCHEMBL10201196

SCHEMBL10201196

O=C(Nc1ccc(O)c(Br)n1)c1cccnc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.66
SMN1; SMN2 Q16637 3/20 0.56
HDAC1 Q13547 3/20 0.54
HDAC6 Q9UBN7 1/20 0.54
LMNA P02545 1/20 0.54
HIF1A Q16665 1/20 0.54
KCNMA1 Q12791 1/20 0.53
ROCK2 O75116 1/20 0.52
ROCK1 Q13464 1/20 0.52
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
KMT2A Q03164 1/20 0.49
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
HTT P42858 1/20 0.48
HDAC3 O15379 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201190 0.82 HSD17B10 (0.64) HSD17B10SMN1; SMN2LMNAPOLBGAA
SCHEMBL1520345 0.74 HSD17B10 (0.65) HSD17B10NPC1RAB9AKMT2A
SCHEMBL11591966 0.74 LMNA (0.69) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL29899004 0.73 MAPK8 (0.62) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL17803405 0.73 GAA (0.60) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL23015764 0.73 HSD17B10 (0.64) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL22673128 0.73 HSD17B10 (0.56) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL23410523 0.73 MAPK8 (0.62) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL6642201 0.73 KMT2A (0.67) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA
SCHEMBL10752976 0.73 SMN1; SMN2 (0.60) HSD17B10SMN1; SMN2HDAC1HDAC6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-8569336-B2 Compounds for the treatment of inflammatory disorders TONG LING (US) 2013-10-29 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TONG LING (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015926-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 HSD17B10 256/4885SMN1; SMN2 2209/4885HDAC1 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.